PlateletBio announces $75.5M Series B to extend autoimmune cell therapy
More than two years after PlateletBio landed its first round of fundraising and a contract with the US government, the company announced its Series B round Thursday.
The preclinical stage biotech out of Watertown, MA announced it raised $75.5 million. The round was led by new investors SymBiosis, K2 HealthVentures, and Oxford Finance, and already-existing investors.
The financing will go toward preclinical development of its lead platelet-like cell program as a therapy for the autoimmune disease immune throbocytopenia. It will help further develop its platform and manufacturing capabilities, and as a result, the managing partner of SymBiosis, Chidozie Ugwumba, will join the board of directors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.